Sanofi Fights To Hang On To Eloxatin

Law360, New York (June 15, 2007, 12:00 AM EDT) -- In a move to defend its claim to the U.S. market, Sanofi-Aventis U.S. LLC sued Sandoz Inc. Thursday for allegedly infringing a patent for its popular colon cancer drug, which a handful of other countries have already rejected.

The New Jersey district court case says that Sandoz filed an Abbreviated New Drug Application with the Food and Drug Administration for a generic version of oxaliplatin, which Sanofi holds the patents for and markets as Eloxatin.

According to the complaint, Sandoz's ANDA called the Sanofi patents, U.S....
To view the full article, register now.